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Abstract: Since the discovery of cisplatin and its potency in anticancer therapy, the development of
metallodrugs has been an active area of research. The large choice of transition metals, oxidation
states, coordinating ligands, and different geometries, allows for the design of metal-based agents
with unique mechanisms of action. Many metallodrugs, such as titanium, ruthenium, gallium,
tin, gold, and copper-based complexes have been found to have anticancer activities. However,
biological application of these agents necessitates aqueous solubility and low systemic toxicity.
This minireview highlights the emerging strategies to facilitate the in vivo application of metallodrugs,
aimed at enhancing their solubility and bioavailability, as well as improving their delivery to tumor
tissues. The focus is on encapsulating the metal-based complexes into nanocarriers or coupling to
biomacromolecules, generating efficacious anticancer therapies. The delivery systems for complexes
of platinum, ruthenium, copper, and iron are discussed with most recent examples.
Keywords: metallodrugs; nanoparticles; dendrimers; nanotubes; liposomes; biomacromolecules;
encapsulation; targeting; micelles

1. Introduction
Cisplatin was the first Food and Drug Administration (FDA)-approved metallodrug for the
treatment of solid tumors. Cisplatin, or cis-diamminedichloroplatinum (II), is a square planar
coordination complex with two chlorine and two amine ligands in cis configuration. The cytotoxic
effects of cisplatin originate from the formation of active cis-[Pt(NH3 )2 (H2 O)2 ]2+ species that bind to
nuclear DNA distorting the helical structure, and interfere with DNA replication and transcription
inducing cancer cell apoptosis [1,2]. However, the major limitation of cisplatin is the formation of active
species in the systemic circulation. The fast exchange of chloride ligands to water leads to high systemic
toxicity and limits the clinical dose of the drug [3]. Therefore, often sub-therapeutic concentrations of
cisplatin reaching cancer cells leads to minor DNA damage, DNA repair, and eventually might lead to
the growth of resistant cells. Developing platinum-resistance is a major problem in cisplatin-based
therapy [4,5]. Carboplatin and oxaliplatin are second-generation platinum complexes approved by
the FDA for use as anticancer drugs. They are characterized with lower toxicity profiles, broader
spectrum of action, and overcoming resistance in some types of tumors. However, analogous to
cisplatin mechanism of action hampers elimination of all problems associated with Pt(II) therapy.
Therefore “trans” geometries [6–9], polynuclear [10–14], or platinum (IV) prodrugs [15,16] have been
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resulting in inadequate bioavailability and low accumulation in the tumors. Therefore, many
approaches have been proposed to address these limitations, and the main strategies focus on
exploring nanotechnology-based systems [34,35]. This minireview discusses the examples of
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half-lives, resulting in inadequate bioavailability and low accumulation in the tumors. Therefore,
many approaches have been proposed to address these limitations, and the main strategies focus on
exploring nanotechnology-based systems [34,35]. This minireview discusses the examples of synthetic
nanoparticles as well as biological carriers used to increase the solubility, reduce the systemic toxicity,
increase cancer-cell delivery, or achieve cancer-specific targeting of metallodrugs.
2. Synthetic Nanocarriers
The important advantages of nano-based systems for drug delivery applications are high
stability, loading capacity, possibility to incorporate hydrophobic or highly toxic drug molecules,
and, depending on the core material used, achieving controlled or sustained drug release. This can
sharply improve the solubility and bioavailability of the drugs, as well as their pharmacokinetics,
while reducing the side effects associated with therapy [36,37]. The nanoparticles can accumulate in
the tumor through the enhanced permeability and retention (EPR) effect [38]. In EPR the nanoparticles
extravasate through the impaired tumor vasculature, and the lack of appropriate lymphatic drainage
leads to their prolonged retention in the tumor tissue. The degree of nanoparticle accumulation in the
tumor via EPR depends on the tumor’s type and size. The most pronounced EPR effect was observed
in pancreatic, colon, breast, and stomach cancers. Also, a higher accumulation of nanoparticles was
found in larger tumors [39].
In addition, the versatility of nanoparticle technologies and coating strategies, allows the design
of nanoparticle systems capable of cancer cell recognition and selective tumor targeting [40–42].
The advantages of nanocarriers heighten the drug payload within the tumor, thereby improving the
therapeutic outcomes. Table 1 summarizes the nanocarrier-based systems for metallodrug delivery
that have entered clinical trials.
Table 1. Representative metallodrug delivery systems that have entered clinical trials.
Delivery
System
Polymeric
nanoparticles

Liposome

Inorganic
Nanoparticles

Active Drug

Formulation

Clinical Status

Tumor Target

Identifier

oxaliplatin

AP5346

Phase II

Head and Neck
cancer

NCT00415298

oxaliplatin

NC-4016

Phase I

Colorectal cancer

NCT03168035

cisplatin

NC-6004

Phase III

Pancreatic cancer

NCT03109158

cisplatin

Lipoplatin

Phase I

Lung cancer

NCT02702700
NCT01861496
NCT00004083

cisplatin

SPI-077

Phase I, II

Ovarian, Breast and
Skin cancer

oxaliplatin

Lipoxal

Phase I

Advanced
gastrointestinal
cancer

NCT00964080

iron oxide

Ferumoxytol

Early Phase I

Glioblastoma

NCT00660543

Data are gathered from www.clinicaltrials.gov.

2.1. Liposomes
Liposomes, discovered in 1960s, are one of the first nanosized vehicles used in drug delivery
applications. They are spherical vesicles having an aqueous core surrounded by lipid bilayers, a similar
morphology to cellular membranes [43]. Liposomes are ideal to encapsulate hydrophilic drugs in an
aqueous core, but the hydrophobic therapeutics can also be entrapped within a lipid bilayer. Liposomes
are considered one of the most successful drug delivery vehicles to date [44], with several formulations
approved by the FDA for anticancer therapy and available in the clinic [43,45].
The liposomal formulations of cisplatin have been the most studied including LiPlaCis, SPI-77,
L-NDDP, or lipoplatin [46,47]. Lipoplatin has successfully completed Phase I, Phase II, and Phase III
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human clinical trials. It is a liposome with diameter of ~110 nm with long in vivo half-life of ~120 h,
and was found to effectively accumulate into tumors, while reducing major toxicities associated with
cisplatin [48,49]. Tumoral accumulations with up to ten to 200-fold increase versus normal tissue were
reported [48,49]. However, the liposomal formulations did not enhance the clinical efficacy of cisplatin,
possibly due to inadequate release of the drug in the tumor [50].
The2019,
liposomal
Inorganics
7, x FOR formulations
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4 of 19
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2.2. Micelles
2.2. Micelles
Micelles are simple nanostructures formed from amphiphilic molecules, they range in size between
Micelles are simple nanostructures formed from amphiphilic molecules, they range in size
5 and 100 nm, and are considered to be suitable for drug delivery applications [54]. Micelles are
between 5 and 100 nm, and are considered to be suitable for drug delivery applications [54]. Micelles
spherical ellipsoid systems that self-assemble in an aqueous environment to form a hydrophobic
are spherical ellipsoid systems that self-assemble in an aqueous environment to form a hydrophobic
monolayer in the core and a polar surface. Micelles disintegrate slowly upon the interaction of polar
monolayer in the core and a polar surface. Micelles disintegrate slowly upon the interaction of polar
groups with water, which leads to pore formation within the hydrophobic part and effective drug
escape from the core.
Micelles delivering metallodrugs have been investigated [55–60]. One strategy involved the
covalent attachment of the drug directly to the micelle to avoid its premature release in the circulation
[55–59]. Sentzel’s group has developed micelles to deliver Pt(II) and Ru(II) complexes to cancer cells
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groups with water, which leads to pore formation within the hydrophobic part and effective drug
escape from the core.
Micelles delivering metallodrugs have been investigated [55–60]. One strategy involved the covalent
attachment of the drug directly to the micelle to avoid its premature release in the circulation [55–59].
Sentzel’s group has developed micelles to deliver Pt(II) and Ru(II) complexes to cancer cells [61–64].
They used various lengths of poly[oligo(ethylene glycol) methyl ether methacrylate] (POEGMEMA) and
1,1-di-tert-butyl 3-(2-(methacryloyloxy)ethyl) butane-1,1,3-tricarboxylate (PMAETC) block copolymers
with pendant bidentate carboxylate ligands to form a carboplatin-like complex directly on the
polymer [62]. The length of hydrophobic PMAETC block was varied and micelles with the shortest
PMAETC block showed highest Pt(II) loading of 83%, smallest hydrodynamic diameter of ~77 nm,
faster Pt(II) release, and higher cytotoxicity towards lung cancer cells than micelles with longer
PMAETC blocks. A similar approach was used to prepare ruthenium micelles of RAPTA-C [RuCl2
(p-cymene)-(PTA)] [63]. RAPTA-C limits growth of solid tumor metastases, and its mechanism of
action relies on inducing cancer cell apoptosis by triggering G2/M phase arrest. However, RAPTA-C
suffers from poor delivery efficacy [65]. The amphiphilic polymers containing the water-soluble
1,3,5-phosphaadamantane (PTA) ligand were used to attach RAPTA-C [63]. The polymers were
modified with fluorescein enabling in vitro evaluation of the micelle uptake by cancer cells.
Encapsulation into micelles showed increased cellular uptake of RAPTA-C and a ten-fold increase in
toxicity in ovarian cancer cell lines, when compared to a free drug.
2.3. Polymeric Nanoparticles
Poly(lactic-co-glycolic) acid (PLGA) [66] is an FDA-approved biodegradable slow-releasing
polymer exhibiting a wide range of erosion times [67]. At present, many PLGA-based formulations
are at the pre-clinical stage [68,69]. Recently, PLGA nanoparticles incorporating ruthenium-based
radiosensitizer, Ru(phen)2 (tpphz)2+ (phen = 1,10-phenanthroline, tpphz = tetrapyridophenazine)
(Ru1), were investigated as a combination therapy in oesophageal cancer cells [70]. The nanoparticles
were formed via a double emulsion evaporation method from a polymer:drug mixture at the ratio of
1:6.25, respectively, resulting in drug loading of 1.14%. The surface of the nanoparticles was modified
with metal ion chelator diethylenetriaminepentaacetic acid (DTPA) for 111 In radiolabelling, and the
targeting ligand for human epidermal growth factor receptor (EGFR). The schematic of the nanoparticle
is shown in Figure 3A. The Ru1 is electron-dense and can be clearly distinguished inside the PLGA
core. The in vitro studies showed higher nanoparticle uptake in EGFR-overexpressing oesophageal
cancer cells, when compared to cells with normal EGFR levels. Importantly, co-delivery of 111 In
and Ru1 led to synergistic cytotoxic effects through 111 In radiotoxicity and DNA damage fortified
by Ru1 intercalating properties, resulting in enhanced therapeutic outcomes (Figure 3B). In another
approach, Ru(II) was encapsulated into PLGA nanoparticles with a diameter of ~100 nm and evaluated
in two-photon-excited photodynamic therapy (PDT) [71]. The nanoparticles showed cytotoxic effects
in vitro on C6 glioma cells.
Yang et al. coordinated Pt (IV) to diamminedichlorodihydroxyplatinum (DHP) polymer or its
dicarboxyl derivative diamminedichlorodisuccinatoplatinum (DSP) [72]. The platinum(IV)–polymer
conjugates were easily reduced in acidic conditions producing active Pt(II) species. The constructs
were cytotoxic in vitro towards breast (MDA-MB-468, MCF-7) and ovarian cancer (SKOV-3) cell lines,
and in vivo evaluation showed accumulation of the conjugates in the tumor.
Earlier reports on Pt(IV) prodrugs delivery using polymeric carriers include the work of
Dhar et al., where Pt(IV) complex was loaded into PEG-PLGA nanoparticles, and the nanoparticle’s
surface was decorated with aptamer targeting ligand for prostate-specific membrane antigen
(PSMA) [73]. The in vitro studies demonstrated higher cytotoxicity of nanoparticle Pt(IV) formulation
towards prostate cancer cells than the free drug. Furthermore, Aryal et al. conjugated Pt(IV) to PLA of
PEG-PLA block copolymer, using acid labile bonds [74]. The nanoparticles formed from the construct
had an average diameter of about ~100 nm, and showed a controlled acid-responsive drug release.
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Also, Rieter et al. synthesized the nanoparticles by precipitation of disuccinatocisplatin (DSCP) with
Tb3+ ions [75]. The nanoparticles were stabilized with a shell of amorphous silica and showed higher
Inorganics
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2.4. Carbon Nanotubes (CNTs)
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2.4. Carbon
Nanotubes
(CNTs)
vehicles primarily due to their excellent cellular penetration ability, and hollow interior capable of
Carbon nanotubes, high aspect ratio nanomaterials, have been considered as drug delivery
incorporating high payloads of drug molecules. The major challenge in biological use of CNTs is their
vehicles primarily due to their excellent cellular penetration ability, and hollow interior capable of
toxicity. However, large surface area of CNTs and the choice of surface chemistries can potentially
incorporating high payloads of drug molecules. The major challenge in biological use of CNTs is their
alleviate this problem by introducing additional functionalities to increase biocompatibility [77].
toxicity. However, large surface area of CNTs and the choice of surface chemistries can potentially
Several carbon nanotube-based carriers have been developed for Pt(IV) prodrug delivery [78–83].
alleviate this problem by introducing additional functionalities to increase biocompatibility [77].
In one example, two different diameters of multi-walled carbon nanotubes were examined to deliver
Several carbon nanotube-based carriers have been developed for Pt(IV) prodrug delivery [78–
Pt(IV) to HeLa cells [82]. The cells internalized the CNTs-Pt effectively, with the larger diameter
83]. In one example, two different diameters of multi-walled carbon nanotubes were examined to
deliver Pt(IV) to HeLa cells [82]. The cells internalized the CNTs-Pt effectively, with the larger
diameter CNTs-Pt showing higher cytotoxicity than the smaller one or free drugs. Importantly, low
toxicity was observed after the incubation of CNTs-Pt with murine macrophages.
Zhang et al. encapsulated ruthenium(II) complexes into single-walled carbon nanotubes for
photothermal and photodynamic therapy with near-infrared (NIR) irradiation [84]. Ru(II) complexes,
were sonicated with SWCNTs for 4 h to produce Ru@SWCNTs. The schematic of the construct and
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A similar approach was used by Wang et al., where a Ru(II) polypyridyl complex was loaded
2.5. Inorganic Nanoparticles
in multi-walled carbon nanotubes producing RuPOP@MWCNTs delivery system [85]. The cellular
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oxygen species (ROS) overproduction, which induced cancer cell apoptosis.
Several groups have studied gold nanoparticles as a delivery system for platinum-based agents
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either through the ligand exchange with chloride ions, or Au–S bond cleavage and peptide–folate–Pt
conjugate release from the surface of the nanoparticle. The cytotoxic effects were evaluated against
folate-overexpressing human epidermoid carcinoma KB cells, where the nanoparticles showed high
biological activity.
Pramanik et al. also used gold nanoparticles to deliver a copper(II) diacetyl-bis(N4methylthiosemicarbazone) complex [92]. The loading strategy involved the attachment of the Cu(II)
Inorganics 2019,
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Figure 5. (A) Schematic illustration for the synthesis of PEG stabilized gold nanoparticles and
Figure 5. (A) Schematic illustration for the synthesis of PEG stabilized gold nanoparticles and
nanoconjugates. (B) In vivo anticancer activity of AuNPs in mice bearing HeLa xenografts. *** indicates
nanoconjugates. (B) In vivo anticancer activity of AuNPs in mice bearing HeLa xenografts. ***
p < 0.001. Reprinted with permission from reference [92].
indicates p < 0.001. Reprinted with permission from reference [92].

Liu et al. synthesized folic acid-conjugated selenium nanoparticles as a carrier for ruthenium
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Mesoporous silica nanoparticles also emerged as nanocarriers for metal-based complexes.
death.
The advantages of silica carriers include chemical stability, ease of surface modification with
Mesoporous silica nanoparticles also emerged as nanocarriers for metal-based complexes. The
different functional groups for subsequent drug conjugation, as well as a tunable pore diameter [95].
advantages of silica carriers include chemical stability, ease of surface modification with different
Gomes-Ruiz’s group employed mesoporous silica nanoparticles as carriers for tin, titanium,
functional groups for subsequent drug conjugation, as well as a tunable pore diameter [95]. Gomesand ruthenium complexes [34,96–103]. Interestingly, they observed that the entire nanostructure
Ruiz’s group employed mesoporous silica nanoparticles as carriers for tin, titanium, and ruthenium
of mesoporous silica–drug conjugate was involved in triggering cancer cell apoptosis, and only a
complexes [34,96–103]. Interestingly, they observed that the entire nanostructure of mesoporous
small release of the encapsulated metallodrug was contributing to cytotoxic effects. This work was
silica–drug conjugate was involved in triggering cancer cell apoptosis, and only a small release of the
pioneering as it pointed towards a non-classical mechanism of action usually observed for these types
encapsulated metallodrug was contributing to cytotoxic effects. This work was pioneering as it
pointed towards a non-classical mechanism of action usually observed for these types of systems.
This was highlighted in a recent publication by this group, where the complexes of tin and titanium
were immobilized onto silica-based material SBA-15 (Santa Barbara Amorphous-15) modified with
the aminodiol ligand 3-[bis(2-hydroxyethyl)amino] propyltriethoxysilane [102]. This construct was
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of systems. This was highlighted in a recent publication by this group, where the complexes of tin and
titanium were immobilized onto silica-based material SBA-15 (Santa Barbara Amorphous-15) modified
with the aminodiol ligand 3-[bis(2-hydroxyethyl)amino] propyltriethoxysilane [102]. This construct
was used as a support to attach diorganotin(IV) compound, SnPh2 Cl2 , and two titanocene derivatives,
TiCp2 Cl2 ([Ti(η5 -C5 H5 )2 Cl2 ] and TiCpCpPhNfCl2 ([Ti(η5 -C5 H5 ) (η5 -C5 H4 CHPhNf)Cl2 ] (Ph = C6 H5 ;
Nf = C10 H7 ). The tin loading was determined to be 12 wt % and titanium 3.2 and 2.0 wt %, respectively.
The pore diameter of mesoporous silica decreased from 5.4 nm to 3.3 nm after the drug conjugation.
The apoptotic effects have been studied in three different cancer cell lines: Human DLD-1 colon
carcinoma, A2780 ovarian carcinoma and A431 epidermoid carcinoma. Although the observed drug
release was low, only 10% of loaded tin and 1% of titanium from the constructs, the cancer cell viability
was markedly reduced. It was found that silica-tin nanostructures induce apoptosis through the
Fas–FasL system while silica-titanium constructs interfere with the TNF-α pathway. Therefore, it was
concluded that the factors contributing to cancer cell death were small release of metallodrug from
mesoporous silica as well as the presence of the nanoconstruct itself.
Other groups have investigated biomimetic hydroxyapatite nanocrystals as the delivery
vehicles for platinum (II) [104–106]. The advantage of hydroxyapatite nanostructures is their
intrinsic biocompatibility with biological systems since they are mineral constituents of bone [107].
For example, Natile’s group used hydroxyapatite nanocrystals to deliver two platinum derivatives
of cis-1,4-diaminocyclohexane ([PtX2 (cis-1,4-DACH)], X2 = Cl2 and 1,1-cyclobutanedicarboxylate
(CBDCA) [105]. The complexes were adsorbed on the surface of the nanocrystals and the
systems were tested in different cancer cell cultures. The in vitro studies included human colon
(LoVo) and lung (A549) cancer cells as well as human osteosarcoma cells sensitive (U2OS) and
resistant (U2OS/Pt) to cisplatin. The release of the complexes was accelerated at lower pH
associated with the tumor’s microenvironment, upon dissolution of hydrohyapatite nanocrystals.
The hydroxyapatite-PtX2 (cis-1,4-DACH) nanoconstruct has proven to be more cytotoxic than the other
derivative, primarily due to its fast release from the nanocrystals.
2.6. Dendrimers
Dendrimers are nanoscale macromolecules that have a spherical three-dimensional morphology
and are formed by a successive addition of layers of branching groups. The step-wise synthesis of
dendrimers provides the control over the number of branches, producing different generations of
the dendrimers with distinct size and molecular weight. The external layer of the dendrimer has
functional groups that can provide solubility or serve as an anchoring site to attach additional ligands.
The drug molecules can be encapsulated in the interior of the branches or attached to the surface
groups. Dendrimers can be composed of any type of monomer, and thus a variety of dendrimers exists,
with many showing low cytotoxicity profiles while applied in biological settings [108].
Dendrimers have been investigated for the delivery of metallocomplexes [109–114]. For example,
Gouveia et al. produced low generation dendrimers modified with an organometallic compound
of Ru(II) [110]. The nitrile poly(alkylidenimine) dendritic scaffolds of different sizes were modified
with an organometallic fragment [Ru(η5 -C5 H5 )(PPh3 )2 ]+ attached to the peripheral end groups of the
dendrimers. The Ru(II)-dendrimers showed high biological activity in vitro against different cancer
cell lines, such as Caco-2 (colon adenocarcinoma), CAL-72 (osteocarcoma), and MCF-7 (breast cancer).
In addition, the metallodendrimers showed cytotoxicity higher than cisplatin in ovarian A2780 cells
and A2780-platinum resistant cells.
In another example, Smith’s group studied organometallic dendrimers of diaminobutane
containing ruthenium(II)–p-cymene, ruthenium(II)–hexamethylbenzene, rhodium(III)-cyclopentadienyl,
and iridium(III)–cyclopentadienyl moieties [113]. The biological activity of the metallodendrimers was
evaluated in vitro using A2780 cisplatin-sensitive and A2780cisR cisplatin-resistant human ovarian
cancer cell lines as well as a non-tumorigenic HEK-293 human embryonic kidney cell line. All constructs
showed cytotoxicity but the most pronounced effects were observed for ferrocenyl-derived
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ruthenium(II)–hexamethylbenzene metallodendrimer. Importantly, all metallodendrimers showed
lower cytotoxicity towards non-malignant cells. Interestingly, it was proposed that the possible mode
of action of these constructs might involve non-covalent interactions with DNA.
Li et al. formulated supramolecular dendritic system for Pt(II) delivery (Figure 6). The building
blocks included the lipoic acid functionalized dendrons, Pt(II)–PEG conjugate, and a NIR fluorophore
for in vivo imaging purposes [114]. The core was bridged via disulfide bonds and incorporated
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3. Biological Carriers
3. Biological Carriers
Natural biomacromolecules, such as proteins and peptides, are attractive carriers for small drug
Natural biomacromolecules, such as proteins and peptides, are attractive carriers for small drug
molecules due to their inherent biodegradability, biocompatibility, low toxicity, and high aqueous
molecules due to their inherent biodegradability, biocompatibility, low toxicity, and high aqueous
solubility. Additionally, biological drug carriers can recognize tumor markers overexpressed by cancer
solubility. Additionally, biological drug carriers can recognize tumor markers overexpressed by
cells, which has been readily used in targeted therapies. Finally, peptides and proteins are easy to
cancer cells, which has been readily used in targeted therapies. Finally, peptides and proteins are
manufacture and stable, which is often challenging to accomplish with synthetic nanoparticles [115].
easy to manufacture and stable, which is often challenging to accomplish with synthetic nanoparticles
[115].
3.1.
Peptides
The delivery of metallodrugs using peptides as biological carriers has been investigated.
3.1. Peptides
Wlodarczyk et al. used the SV40 large T antigen-derived PKKKRKV peptide known as nuclear
The delivery
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Wlodarczyk
et
al.
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study,
localization
sequence
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therapy
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the
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with
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study,
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terminal
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was modified
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derivative
during the
solid-state
Pt(II).
Theofschematic
of the construct
is presented
in Figure
The solubility
of the
Pt-NLS peptide
hybrid
synthesis, and the carboplatin-like complex was formed directly on the peptide from activated Pt(II).
The schematic of the construct is presented in Figure 7A. The solubility of the Pt-NLS hybrid was 50
mg/mL, which was much higher than that of native carboplatin (10 mg/mL). The construct was found
to effectively translocate through the cellular membrane (Figure 7B) and deliver platinum to the
nucleus. Importantly, the Pt-NLS hybrid showed high biological activity in ovarian cancer cell lines,
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Similarly, Noor
et al. used the NLS peptide to form ferrocene–NLS conjugate [117]. The ferrocene
3.2. Antibodies
and Proteins
carboxylic acid was attached to the N-terminus of the NLS peptide. The evaluation of the conjugate
Antibody–drug
(ADC)
represent
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that combines
with Hep
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not show the
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effects.
However,
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also observed
enhanced
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schematic of the construct is shown in Figure 8A. This strategy resulted in ADC-Pt(II) constructs with
higher stability than conventional ADCs connected via maleimide-based chemistry, reducing the
drug exchange with blood serum albumin and off-target toxicity. The ADC-Pt(II) demonstrated high
toxicity in vitro, and the in vivo studies using the A549 non-small cell lung cancer model showed
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3.2. Antibodies and Proteins
Antibody–drug conjugates (ADC) represent a highly potent class of therapeutics that combines
precise cancer cell recognition by monoclonal antibodies mAb with cell killing by small molecule drugs.
The ADC conjugates with metallodrugs have also been developed. Recently, Gupta et al. reported a
Pt(II)-based linker that can re-bridge the inter-chain cysteines in the antibody [119]. The schematic of
the construct is shown in Figure 8A. This strategy resulted in ADC-Pt(II) constructs with higher stability
than
conventional
ADCs
via maleimide-based chemistry, reducing the drug exchange
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with a tumor growth inhibition (TGI) of 55%. Reprinted with permission from reference [119].

4. Conclusions
4. Conclusions
In summary, nanocarriers have proven to be powerful tools in enhancing the delivery of
In summary, nanocarriers have proven to be powerful tools in enhancing the delivery of
metallordrugs to cancer cells. Nanotechnology offers versatility in nanostructure synthesis methods and
metallordrugs to cancer cells. Nanotechnology offers versatility in nanostructure synthesis methods
choice of materials, giving the control over physicochemical properties of the final nanodelivery system.
and choice of materials, giving the control over physicochemical properties of the final nanodelivery
This also allows encapsulating metallodrugs at sufficient payload, increasing their solubility, limiting
system. This also allows encapsulating metallodrugs at sufficient payload, increasing their solubility,
the release in the systemic circulation preventing toxicities, and eventually heightening their efficacy
limiting the release in the systemic circulation preventing toxicities, and eventually heightening their
efficacy in vivo. The main advantage of long-circulating nanocarriers is their accumulation in the
tumor via EPR, which leads to increased drug payloads in the tumor. Moreover, the nanodelivery
vehicles can be decorated with targeting ligands that further enhance the entry into cancer cells via
receptor-mediated endocytosis. Furthermore, incorporating fluorescent dyes to the nanocarriers
allows unique theranostic applications. Another attractive strategy involves conjugation of
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in vivo. The main advantage of long-circulating nanocarriers is their accumulation in the tumor via
EPR, which leads to increased drug payloads in the tumor. Moreover, the nanodelivery vehicles can be
decorated with targeting ligands that further enhance the entry into cancer cells via receptor-mediated
endocytosis. Furthermore, incorporating fluorescent dyes to the nanocarriers allows unique theranostic
applications. Another attractive strategy involves conjugation of metallodrugs to biomacromolecules,
such as antibodies or functional peptides. They are cheap, easy to produce, stable, and, most
importantlym inherently biodegradable. Also, superior cancer cell recognition can be achieved
using mAb, which, coupled to metallodrugs, amplifies their intracellular delivery. The biological
carriers might be extended even further to include vitamin-mediated drug targeting [122,123]
or steroid-conjugates [124]. These systems have the potential to evolve into highly efficacious
metallodrug-based therapies.
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